May 6, 2020 / 1:50 PM / a month ago

BRIEF-Gilead Says Incurred $50 Mln Of Manufacturing Scale-Up, Clinical Trial Costs For Remdesivir In Q1

May 6 (Reuters) - Gilead Sciences Inc:

* GILEAD SCIENCES SAYS INCURRED ABOUT $50 MILLION OF MANUFACTURING SCALE-UP, CLINICAL TRIAL COSTS FOR REMDESIVIR DURING Q1 - SEC FILING

* GILEAD SCIENCES SAYS ANTICIPATE ACCELERATING REMDESIVIR INVESTMENTS IN FUTURE QUARTERS

* GILEAD SCIENCES - THERE IS POSSIBILITY THAT CO MAY EXPERIENCE DELAYS WITH NDA FOR FILGOTINIB FOR TREATMENT OF RHEUMATOID ARTHRITIS FILED WITH FDA

* GILEAD SCIENCES - THERE IS POSSIBILITY CO MAY EXPERIENCE DELAYS WITH NDA, MAA FOR KTE-X19 FOR TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA Source text: (bit.ly/2zXgYuu) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below